News

MB07811 reduced hepatic fat content in all animal models tested while T3, the natural TR ligand, failed to reduce hepatic fat content in two of the three models.

The purpose of the Phase II study is to confirm the positive results obtained in the ongoing open-label study. The study will include 60 patients and will be

The data was presented by Dr. David Morrow of the Timi Study Group at the American Heart Association Scientific Sessions in Orlando, Florida. Ranexa (ranolazine) is believed to

This clinical trial focused on the immunogenicity of a three-dose BioThrax (Anthrax Vaccine Adsorbed) regimen when used for post-exposure prophylaxis (PEP) in adults. The primary objective of the

This grant is part of the $22.6 million the Gates Foundation has granted to the University of North Carolina led consortium in 2006 to fund Phase III clinical

Under the collaboration, Epix has said, it is entitled to receive a $3 million milestone payment in the next 30 days. In August, Epix announced that it had

In this study, R7128 demonstrated potent antiviral activity and was generally safe and well-tolerated, and all 40 patients completed the study. R7128 is being developed in collaboration with

The studies, Enable 1 and Enable 2, will measure the ability of eltrombopag to raise platelet counts sufficiently enough to enable the initiation of antiviral therapy and to

Because Gardasil is designed to prevent HPV 6, 11, 16 and 18 disease, rather than treat an ongoing infection, the primary analysis of the study was conducted among